Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00246961
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
Exclusion Criteria
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Arimidex's impact on quality of life in breast cancer patients switching from tamoxifen?
How does Arimidex compare to tamoxifen in managing aromatase inhibitor-related adverse events in postmenopausal breast cancer patients?
What biomarkers correlate with improved outcomes when switching from tamoxifen to Arimidex in estrogen receptor-positive breast cancer?
What are the long-term efficacy and safety outcomes of Arimidex versus other aromatase inhibitors in AstraZeneca's breast cancer studies?
How do aromatase inhibitors like Arimidex influence tumor microenvironment dynamics in hormone-sensitive breast cancer?
Trial Locations
- Locations (2)
Research Site
🇳🇱Zutphen, Netherlands
Research SIte
🇳🇱Dordrecht, Netherlands
Research Site🇳🇱Zutphen, Netherlands